Tiftikçioğlu Bedile İrem
Baskent University Faculty of Medicine, Department of Neurology, Zübeyde Hanım Practice and Research Hospital, İzmir, Turkey.
Noro Psikiyatr Ars. 2018;55(Suppl 1):S46-S48. doi: 10.29399/npa.23330.
It is important to assess the clinical outcome in patients with multiple sclerosis (MS) both during individual clinical follow-up and in clinical trials. The National MS Society's Clinical Outcomes Assessment Task Force has developed and recommended a multidimensional clinical outcome measure, namely Multiple Sclerosis Functional Composite (MSFC). This enables to measure the impact of MS in three key clinical dimensions: leg function and ambulation, arm and hand function, and cognitive function. Raw scores in different measurement scales are transformed into standard comparable scores (z-scores) and an overall composite score is calculated. In this review, the rationale behind the MSFC, administration and calculation of the composite score is discussed in detail.
在个体临床随访期间以及临床试验中评估多发性硬化症（MS）患者的临床结局都很重要。美国国家多发性硬化症协会临床结局评估特别工作组已制定并推荐了一种多维临床结局测量方法，即多发性硬化症功能综合评分（MSFC）。这能够在三个关键临床维度上测量MS的影响：腿部功能与行走、手臂和手部功能以及认知功能。不同测量量表中的原始分数被转换为标准可比分数（z分数），并计算出总体综合评分。在本综述中，将详细讨论MSFC背后的原理、综合评分的管理和计算。
